Kwang‐Su Park

ORCID: 0000-0002-1910-3937

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 26 papers. Top paper: “Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets”.

Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets

Journal of the American Chemical Society(2022)10.1021/jacs.2c09255

N/A

0.736DataRank · unranked

134 citations

Yue Zhong, Hyerin Yim, Xiaobao Yang, Kwang‐Su Park, Ling Xie +7 more

Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome

Molecular Therapy(2024)10.1016/j.ymthe.2024.05.034

N/A

0.508DataRank · unranked

14 citations

Yan Xiong, Mi‐Ae Jang, Kwang‐Su Park, Meaghan Donahue, Julia Velez +3 more

A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models

Science Translational Medicine(2021)10.1126/scitranslmed.abj1578

N/A

0DataRank · unranked

158 citations

Dongxu Li, Jithesh Kottur, Yudao Shen, Huen Suk Kim, Kwang‐Su Park +14 more

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Journal of the American Chemical Society(2021)10.1021/jacs.1c04841

N/A

0DataRank · unranked

144 citations

Fanye Meng, Kwang‐Su Park, Hyerin Yim, Julia Velez, Prashasti Kumar +11 more

A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells

Cell chemical biology(2021)10.1016/j.chembiol.2021.08.004

N/A

0DataRank · unranked

62 citations

Fanye Meng, Kwang‐Su Park, Aaron J. Storey, Weida Gong, Yi‐Hsuan Tsai +12 more

A First-in-Class, Highly Selective and Cell-Active Allosteric Inhibitor of Protein Arginine Methyltransferase 6

Journal of Medicinal Chemistry(2021)10.1021/acs.jmedchem.0c02160

N/A

0DataRank · unranked

27 citations

Fengling Li, Magdalena M. Szewczyk, Levon Halabelian, Irene Chau, Mohammad S. Eram +22 more

EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis

Nature Cell Biology(2022)10.1038/s41556-022-00850-x

N/A

0DataRank · unranked

184 citations

Xufen Yu, Weida Gong, Xijuan Liu, Kwang‐Su Park, Anqi Ma +12 more

Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2

ACS Pharmacology & Translational Science(2022)10.1021/acsptsci.2c00100

N/A

0DataRank · unranked

62 citations

Chris Anderson, Kwang‐Su Park, H. Ümit Kanıskan, Anqi Ma, Yudao Shen +6 more

Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.2c00807

N/A

0DataRank · unranked

58 citations

Chenxi Xu, Kwang‐Su Park, H. Ümit Kanıskan, Gang Greg Wang, Jian Jin +1 more

Discovery of the First-in-Class G9a/GLP Covalent Inhibitors

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.2c00652

N/A

0DataRank · unranked

46 citations

Yan Xiong, Hyerin Yim, Julia Velez, Nicolas Babault, Prashasti Kumar +3 more

A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation

Nucleic Acids Research(2022)10.1093/nar/gkac861

N/A

0DataRank · unranked

41 citations

Kwang‐Su Park, Xufen Yu, Weida Gong, H. Shelton Earp, Gang Greg Wang +3 more

Discovery of Potent, Selective, and In Vivo Efficacious AKT Kinase Protein Degraders via Structure–Activity Relationship Studies

Journal of Medicinal Chemistry(2022)10.1021/acs.jmedchem.1c02165

N/A

0DataRank · unranked

39 citations

Jia Xu, Yudao Shen, Kaitlyn M. Cahuzac, Kwang‐Su Park, Brandon Dale +4 more

A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant promoting oncogene activation and tumorous transformation

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.08.04.502794

N/A

0DataRank · unranked

5 citations

Kwang‐Su Park, Xufen Yu, Weida Gong, H. Shelton Earp, Gang Greg Wang +3 more

Targeted degradation of PRC1 components, BMI1 and RING1B, via a novel protein complex degrader strategy

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.11.19.517138

N/A

0DataRank · unranked

2 citations

Lihuai Qin, Md Kabir, Kaixiu Luo, Brandon Dale, Yue Zhong +5 more

Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy

Advanced Science(2023)10.1002/advs.202205573

N/A

0DataRank · unranked

28 citations

Lihuai Qin, Md Kabir, Kaixiu Luo, Brandon Dale, Yue Zhong +5 more

Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication

medRxiv(2023)10.1101/2023.10.25.23297491

N/A

0DataRank · unranked

6 citations

Ryan N. Sheehy, Yan Xiong, Adil Muneer, John A. Wrobel, Kwang‐Su Park +13 more

Novel brain-penetrant inhibitor of G9a methylase blocks Alzheimer’s disease proteopathology for precision medication

Research Square(2023)10.21203/rs.3.rs-2743792/v1

N/A

0DataRank · unranked

1 citations

Ling Xie, Ryan N. Sheehy, Yan Xiong, Adil Muneer, John A. Wrobel +13 more

Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2

European Journal of Medicinal Chemistry(2024)10.1016/j.ejmech.2024.116154

N/A

0DataRank · unranked

37 citations

Brandon Dale, Kwang‐Su Park, H. Ümit Kanıskan, Xufen Yu, Jian Jin +1 more

Discovery of the First-in-Class G9a/GLP PROTAC Degrader

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.3c02394

N/A

0DataRank · unranked

12 citations

Yulin Han, Hyerin Yim, Peiyi Yang, Zhijie Deng, Kwang‐Su Park +5 more

Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c00538

N/A

0DataRank · unranked

11 citations

Lihuai Qin, Kaixiu Luo, Yan Xiong, Rebecca A. Sidi, Kwang‐Su Park +2 more

Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor

Journal of Medicinal Chemistry(2024)10.1021/acs.jmedchem.4c00121

N/A

0DataRank · unranked

3 citations

Holger Greschik, C. Johansson, Ludwig Seifert, Vicki Gamble, Kwang‐Su Park +14 more

Discovery of the First-in-class G9a/GLP PROTAC Degrader

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.02.26.582210

N/A

0DataRank · unranked

2 citations

Yulin Han, Hyerin Yim, Peiyi Yang, Zhijie Deng, Kwang‐Su Park +5 more

Development of a brain-penetrant G9a methylase inhibitor to target Alzheimer’s disease-associated proteopathology

Nature Communications(2025)10.1038/s41467-025-59128-z

N/A

0DataRank · unranked

9 citations

Ryan N. Sheehy, Adil Muneer, Yan Xiong, John A. Wrobel, Feng Zhang +20 more

Discovery of a First-in-Class Protein Arginine Methyltransferase 6 (PRMT6) Covalent Inhibitor

Journal of Medicinal Chemistry(2020)10.1021/acs.jmedchem.0c00406

N/A

0DataRank · unranked

42 citations

Fengling Li, Magdalena M. Szewczyk, Levon Halabelian, Kwang‐Su Park, Irene Chau +11 more

Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma

iScience(2025)10.1016/j.isci.2025.112387

N/A

0DataRank · unranked

3 citations

Reshmee Bhattacharya, Seungyeul Yoo, Feng Jiang, Eric Park, Genesis Lara Granados +8 more

A First-in-class, Highly Selective and Cell-active Allosteric Inhibitor of Protein Arginine Methyltransferase 6 (PRMT6)

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.12.04.412569

N/A

0DataRank · unranked

1 citations

Fengling Li, Magdalena M. Szewczyk, Levon Halebelian, Irene Chau, Mohammad S. Eram +19 more